Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 250, Issue 10, 2012, Pages 1435-1440

  Mathalone, Nurit ^a,b   Arodi Golan, Anat ^a,b   Sar, Shaul ^a,b   Wolfson, Yulia ^a,b   Shalem, Mordechai ^a,b   Lavi, Idit ^a   Geyer, Orna ^a,b  

^a CARMEL MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Age related macular degeneration (AMD); Bevacizumab; Intraocular pressure (IOP)

Indexed keywords

BEVACIZUMAB;

AGE DISTRIBUTION; AGED; APHAKIA; ARTICLE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PREVALENCE; PRIORITY JOURNAL; PSEUDOPHAKIA; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PREVALENCE; RETREATMENT; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TIME FACTORS; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84867747951     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-012-1981-0     Document Type: Article

References (14)

1. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897-1908
2. Kahook MY, Kimura AE, Wong LJ (2009) Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 40:293-295
3. Sniegowski M, Mandava N, Kahook MY (2010) Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J 4:28-29
4. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM (2008) Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 246:955-958
5. Adelman RA, Zheng Q, Mayer HR (2010) Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 26:105-110
6. Tseng JJ, Vance SK, Della Torre KE, Mendonca LS, Cooney MJ, Klancnik JM, Sorenson JA, Freund KB (2011) Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 2011. doi:10.1097/IJG. 0b013e31820d7d19
7. Good TJ, Kimura AE, Mandava N, Kahook MY (2011) Sustained elevation of intraocular pressure after intravitreal injections of anti- VEGF agents. Br J Ophthalmol 95:1111-1114
8. Hohn F, Mirshahi A (2010) Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application. Graefes Arch Clin Exp Ophthalmol 248(10):1371-1375
9. Leske MC, Connell AM, Schachat AP, Hyman L, Barbados Eye Study Group (1994) The Barbados Eye Study: prevalence of openangle glaucoma. Arch Ophthalmol 112:821-829
10. Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, Nickerson RJ, Pool J, Colton TL, Ganley JP, Loewenstein JI, Dawber TR (1980) The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 24 (suppl):335-610
11. AGIS Investigators (2002) The Advanced Glaucoma Intervention Study (AGIS): Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophthalmol 134:499-512
12. Bakri SJ, Larson TA, Edwards AO (2008) Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 246:779-781
13. Liu L, AmmarDA, Ross LA,Mandava N, KahookMY, Carpenter JF (2011) Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Investig Ophthalmol Vis Sci 52:1023-1034
14. Kahook MY, Liu L, Ruzycki P, Mandava N, Carpenter JF, Petrash JM, Ammar DA (2010) High-molecular-weight aggregates in repackaged bevacizumab. Retina 30:887-892